Norethindrone substituted for megestrol in the treatment of metastatic endometrial carcinoma: Three cases
Megestrol is an effective palliative treatment for endometrial carcinoma. Some persons with progestin-responsive cancer continue on hormonal therapy for months or even years. In persons who respond to megestrol, long term use can cause weight gain and other side effects via activity of the drug at t...
Main Authors: | William L. Read, Sumita Trivedi, Felicia Williams |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2017-11-01
|
Series: | Gynecologic Oncology Reports |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2352578917301078 |
Similar Items
-
Efficacy of megestrol acetate in treatment of 21 young patients with endometrial adenocarcinoma
by: Eftekhar Z, et al.
Published: (2007-05-01) -
Norethindrone Acetate in the Medical Management of Adenomyosis
by: Siddhi Mankame, et al.
Published: (2012-10-01) -
The role of estrogen and progesterone receptors in response rate to megestrol acetate: conservative treatment of stage Ia endometrial adenocarcinoma
by: Yarandi F, et al.
Published: (2010-12-01) -
Efficacy and safety of megestrol in the management of hepatocellular carcinoma: a systematic review of the literature
by: Prashanth Rawla, et al.
Published: (2018-12-01) -
HT update: spotlight on estradiol/norethindrone acetate combination therapy
by: Colleen L Casey, et al.
Published: (2008-03-01)